No products in the cart.
OxyContin OC 80mg β The Complete Medical Guide
Introduction to OxyContin OC 80mg
OxyContin OC 80mg is aΒ high-dose, extended-release oxycodone formulationΒ classified as aΒ Schedule II controlled substance. This maximum-strength version of the original OxyContin (pre-2010 reformulation) is designed forΒ management of severe, around-the-clock pain in opioid-tolerant patients. The “OC” designation indicates itΒ lacks modern abuse-deterrent properties, making it one of the most dangerous prescription opioids when misused.
Oxycontin OC 80mg
OxyContin OC 80mg is a potent prescription opioid pain medication designed for the management of severe, chronic pain. Featuring an extended-release formulation, it provides long-lasting pain relief, allowing patients to manage discomfort for up to 12 hours. The active ingredient, oxycodone, works by altering the brain’s response to pain, offering effective relief for conditions such as cancer pain or chronic back pain. Due to its strength, OxyContin OC 80mg must be taken as prescribed by a healthcare provider to minimize the risk of misuse, dependency, and overdose. Always follow dosing guidelines for safety.
Medical Uses & Indications
FDA-Approved Uses
β
Β Severe chronic painΒ requiring continuous opioid therapy
β
Β Cancer pain managementΒ in highly opioid-tolerant patients
β
Β Pain uncontrolled by lower-dose opioids
Key Clinical Features
β’Β Formulation:Β Original controlled-release (non-abuse deterrent)
β’Β Onset:Β 1-2 hours
β’Β Duration:Β 12-hour controlled release
β’Β Equianalgesic ratio:Β 80mg q12h β 120mg oral morphine daily
β’Β DEA Classification:Β Schedule II (Highest abuse potential)
Pharmacology & Mechanism
Neurochemical Action
β’ Full ΞΌ-opioid receptor agonist
β’ ΞΊ-opioid receptor partial agonist
β’ Potent activation of mesolimbic reward pathway
Metabolic Profile
β’Β Hepatic metabolism:Β CYP3A4 (major), CYP2D6 (minor)
β’Β Active metabolites:Β Oxymorphone (via CYP2D6)
β’Β Elimination half-life:Β 4.5-8 hours (ER formulation)
Dosing & Administration
Strict Eligibility Criteria
β’Β Confirmed opioid tolerance:Β β₯160mg oral morphine equivalent daily
β’Β Stable pain patternΒ (Not episodic/breakthrough)
β’Β Failed trials of abuse-deterrent formulations
Conversion Protocol
Calculate total daily morphine equivalent
Reduce by 25-50% (incomplete cross-tolerance)
Divide by 2 for q12h dosing
Critical Safety Notes
β Β Hospital initiation mandatory
β Β Never crush/chew tabletsΒ (immediate 80mg release risk)
β Β Requires dual prescriber verification
β Β Naloxone rescue kit mandatory
Safety Profile
Common Adverse Effects
β’ Severe constipation (universal)
β’ Nausea/vomiting (50-60%)
β’ Profound sedation
β’ Cognitive impairment
Black Box Warnings
βΒ Extreme addiction and abuse potential
βΒ Life-threatening respiratory depression
βΒ Fatal overdose risk if misused
βΒ Concomitant CNS depressant danger
Risk Mitigation Strategies
Prescribing Safeguards
Specialist pain management consultationΒ required
Triplicate prescription formsΒ in most states
Weekly follow-upsΒ for first 3 months
Random pill counts and UDS
Patient Safety Measures
β’Β Biometric locked storageΒ required
β’Β Mandatory caregiver training
β’Β Medication disposal systemΒ provided
β’Β Absolute alcohol prohibition
Clinical Alternatives
For Severe Chronic Pain
β’Β OxyContin OP (abuse-deterrent formulation)
β’Β MethadoneΒ (For select patients)
β’Β Fentanyl transdermal
Non-Opioid Options
β’Β Intrathecal pump therapy
β’Β Dorsal column stimulation
β’Β Adjuvant medications
Special Population Considerations
| Population | Consideration | Action |
|---|---|---|
| Elderly (β₯65) | CONTRAINDICATED | – |
| Hepatic impairment | CONTRAINDICATED | – |
| Renal (CrCl<30) | CONTRAINDICATED | – |
| Pediatric | CONTRAINDICATED | – |
Reviews
There are no reviews yet.